SK Biopharm’s Anti-epileptic Drug Wins FDA Approval

SEOUL, Nov. 22 (Korea Bizwire) — SK Biopharmaceuticals Co., a biopharmaceutical affiliate of South Korea’s SK Group, said Friday its anti-epileptic drug has won approval from the U.S. Food and Drug Administration (FDA). SK Biopharmaceuticals said the FDA granted approval of XCOPRI, or cenobamate tablets, for the treatment of partial-onset seizures in adults. This is [...]